AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

“Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a ...

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.

In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...

The scope of resistant hypertension has not been quantified, but clinical trials suggest it may affect up to 30 percent of people with high blood pressure.

Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...